Latest News and Press Releases

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a...

SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai...

GOWIN announces GW1AN and GW3A FPGA families for 2026, expanding small and medium FPGA options with efficient integration and flexible sourcing.

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026...

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16...

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib...

SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it...

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official...

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This report...